Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Cyclophosphamide 6Isotretinoin 5thymoglobulin 4fludarabine phosphate 4fludarabine 4aldesleukin 4Topotecan 4Temozolomide 4Melphalan 4Irinotecan 4Etoposide 4ribociclib 3Thiotepa 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Busulfan 3Bone Marrow Transplantation 3Antilymphocyte Serum 3temsirolimus 2omburtamab I-131 2dinutuximab 2Vincristine 2Tretinoin 2TPI-287 2Stem Cell Transplantation 2Rituximab 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroblastoma × 64Cu-SARTATE × Clear all
NCT04023331 2025-09-16

67Cu-SARTATEâ„¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Clarity Pharmaceuticals Ltd

Phase 1/2 Terminated
21 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡